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Abstract: Introduction: Nutritional status impacts the survival of patients with cancer. There are
few studies that investigate the role of nutritional status on breast cancer survival in women with
breast cancer, and even fewer regarding the impact of adhering to the Mediterranean diet (MD).
The present study aims to assess the nutritional status, MD adherence, physical activity levels and
health-related quality of life (HRQOL) in women diagnosed with breast cancer and evaluate these
parameters regarding recurrence-free survival. Methods: A total of 114 women, aged 35–87 years
old, diagnosed with breast cancer in Larissa, Greece, participated in the study. Tumor histopathology
was reported, and anthropometric indices were measured by a trained nurse, while questionnaires
regarding nutritional status (via mini nutritional assessment), HRQOL via EORTC QLQ-C30, physical
activity levels via IPAQ and Mediterranean diet adherence via MedDietScore were administered.
The participants were followed-up for a maximum time interval of 42 months or until recurrence
occurred. Results: A total of 74% of patients were overweight or obese, while 4% of women were
undernourished, and 28% were at risk of malnutrition. After 42 months of follow-up, 22 patients
(19.3%) had relapsed. The median time to recurrence was 38 months (IQR: 33–40 months) and ranged
between 23 to 42 months. Higher levels of MD adherence were significantly associated with lower
body mass index (BMI) values, earlier disease stage, smaller tumor size, absence of lymph node
metastases and better physical activity levels (p < 0.05). Normal nutritional status was significantly
associated with higher BMI values and better health-related quality of life (p ≤ 0.05). In univariate
analysis, patients with higher levels of MD adherence and well-nourished patients had significantly
longer recurrence-free survival (p < 0.05). In multivariate analysis, MD adherence and nutritional
status were independently associated with recurrence-free patients’ survival after adjustment for
several confounding factors (p < 0.05). Conclusions: The impact of MD on time to recurrence is still
under investigation, and future interventional studies need to focus on the role of adhering to the
MD before and after therapy in survival and breast cancer progression. Furthermore, the present
study also highlights the importance of an adequate nutritional status on disease progression, and
the need for nutritional assessment, education and intervention in women with breast cancer.
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1. Introduction
Cancer is one of the most common causes of death worldwide, accounting for one in
six deaths, according to the World Health Organization (WHO). Until 2040, the number
of new cancer diagnoses is estimated to reach 30.2 million with 16.3 million deaths [1].
In 2022, the American Cancer Society estimated 1.9 million new cancer cases diagnosed
and 609,360 cancer deaths for the United States [2]. Breast cancer accounts for one third of
diagnoses in the USA for 2022, and is the second leading cause of death due to cancer, with
15% of cancer deaths being due to breast cancer in the USA [2]. Between 2012–2016, the
incidence of breast cancer slightly increased by 0.3% per year, due to the diagnosis of local
disease [3], as well as higher obesity rates and lower pregnancy rates [4]. It is noteworthy
that the incidence of breast cancer is increasing in both pre-menopausal and menopausal
women, which intensifies the need for early diagnosis and access to treatment [5].
In terms of patient survival, death rates have decreased by 31% from 1991 to 2018 [6,7]
thanks to improved medical care and new healthcare technologies, which facilitate early
diagnosis, more effective and personalized treatments and better patient management. In
fact, 10-year survival from breast cancer has doubled in the last 40 years in the UK [8].
According to the American Cancer Society, the five-year survival from breast cancer is 90%
for all stages [9], while it is 77% for triple-negative cancer of all stages [10], and 41% for the
inflammatory breast cancer [10].
The Mediterranean diet (MD) is the most well-studied dietary pattern, and adherence
to the MD has been associated with lower risk of chronic diseases [11,12], such as cancer,
and breast cancer [13–17]. In fact, the recommendations of the World Cancer Research Fund
(WCRF) [18,19] are in line with the MD dietary pattern. Numerous studies have highlighted
the protective effect of the MD against breast cancer [20–22]. On the other hand, adherence
to a Western-type diet has been associated with higher risk of breast cancer [23–25].
Regarding the progression of the disease and diet, most studies result in non-significant
results [26–30]. In the prospective study by Vrieling et al. [30] with 2522 German postmenopausal women, adherence to a healthy dietary pattern was associated with lower
overall mortality (HR 0.74, 95% CI 0.47–1.15, p-trend 0.02) and breast cancer recurrence
(HR 0.71, 95% CI 0.48–1.06, p-trend 0.02) in patients at stages I-IIIa [30].
Furthermore, a meta-analysis with 41 cohort studies in breast cancer survivors showed
that high intakes of foods that are characteristic of a high quality diet (such as fruits,
vegetables, whole grains, nuts, and pulses), and low intakes of red meat (RR 0.74, 95% CI
0.60–0.90, by three studies), as well as adherence to a high quality diet (RR 0.76, 95% CI
0.60–0.95, three studies) are associated with lower mortality [19]. Another meta-analysis
with 56 observational studies [31] showed that MD adherence was negatively associated
with cancer mortality (RR 0.86, 95% CI 0.81–0.91, 15 studies) and overall mortality (RR 0.92,
95% CI 0.87–0.96, 16 studies).
Malnutrition is a common finding in cancer patients, even at the time of diagnosis.
Its incidence varies between 31–87%, depending on the stage, type, treatment and the
individual patient [32,33]. Weight loss can occur, as a result of elevated energy needs, low
energy intake or impaired absorption of nutrients. In cancer patients, undernutrition may
be due to various factors. Inflammation and catabolism because of the tumor can result in
muscle wasting and weight loss [34] while tumor gastrointestinal obstruction can impair
food intake and absorption, as dysphagia, pain, and vomiting may be present. In addition
to this, the side effects of anticancer treatment, such as anorexia, early satiety, nausea,
vomiting, and oral and intestinal mucositis with dysphagia, diarrhea, hemorrhoids, anal
fissures and modifications in smell and taste affect not only the total energy intake, but also
the nutrient absorption, compromising nutritional status. The poor mental health state of
cancer patients can affect their energy intake, as well [35,36].
Malnutrition can impact the progress of the disease and the survival of the patients.
Studies have shown that weight loss in cancer is associated with poor prognosis, worse
quality of life (QoL), lower physical activity level, increased treatment-related adverse
effects and reduced tumor response to treatment [33,37]. Weight loss at diagnosis has
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been associated with shorter failure-free and overall survival (OS), being identified as an
independent prognostic factor. However, when patients stop losing weight, they have better
OS [38]. Nutritional status is important in breast cancer patients as well, even though few
studies have explored its prognostic value [39]. In fact, pre-operative prognostic nutritional
index (PNI) in triple negative breast cancer patients is an independent prognostic factor of
five-year overall and disease-free survival [40].
Cancer cachexia is usually diagnosed in patients with liver, stomach, colorectal, lung
and head and neck cancers [41]. In women with breast cancer, cancer cachexia is rare, but it
might be under diagnosed [42]. Studies in patients with bone metastases have highlighted
that skeletal muscle mass is affected, revealing a potential association between cancer
cachexia and bone metastasis, that is common in advanced cancer [42].
The prognostic role of the nutritional status in different cancer types has been evaluated
mainly in retrospective studies, revealing a literature gap for prospective studies, especially
in women with breast cancer [39]. Additionally, even though the role of adhering to the
Mediterranean diet for cancer prevention has been very well studied [43], few studies have
explored the role of this dietary pattern regarding cancer survival [44], and breast cancer
survival [27,45].
In view of the above considerations, the aim of the present study is to assess the
nutritional status, the adherence to the Mediterranean diet, physical activity and the healthrelated quality of life in women that were recently diagnosed with breast cancer, and
evaluate these parameters regarding recurrence-free patients’ survival. The present study is
a three-year prospective study, in women that were recently diagnosed with breast cancer
in the University General Hospital of Larissa (Larissa, Greece) and have not yet started
chemotherapy or radiotherapy.
2. Materials and Methods
2.1. Subjects
One hundred and fourteen (114) consecutive women recently diagnosed with breast
cancer took part in the present study. Recruitment to the study began at the time the
results of the biopsy were given to the patients, between the period November 2017 and
September 2018. None of the patients had started treatment. The exclusion criterion for
the study was personal history of cancer. The study has been approved by the Bioethics
Committee of the University of Thessaly (no 24/12 November 2017) and was in compliance
with the declaration of Helsinki of the World Medical Association (52nd WMA General
Assembly, Edinburgh, UK). All patient data are confidential, and the study volunteers
were informed regarding the aim of the study, as well as the confidentiality of their data,
and agreed to voluntarily take part in this study, and signed a consent form. Clarifying
instructions were given to the participants about the completion of questionnaires to
facilitate accurate answers.
2.2. Study Design
Patient information was given by the hospital and the questionnaires were given to
the participants during an interview with a trained dietitian and a nurse. Data regarding
the histopathologic analysis and TNM stage was collected from the patients’ files in which
organ metastases were diagnosed by computed tomography imaging. During the interview,
anthropometric indices (weight, height, body mass Index, mid-arm circumference and
calf circumference) were measured. Validated questionnaires were used. Mini nutritional
assessment (MNA) [46–49] was used to assess nutritional status. The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) [50,51] was used to assess health-related QoL. The Mediterranean diet score
(MedDietScore) was used to assess the adherence to the MD during the past five years [52],
and the international physical activity questionnaire (IPAQ) was used to assess physical
activity levels [53,54].
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Anthropometric parameters were measured by a trained dietitian and a trained nurse
according to protocol [55,56]. Weight was measured using the same electronic scale, and
height was measured using a portable stadiometer. A non-elastic measuring tape was used
to measure the mid-arm and calf circumference. The participants were followed-up for a
maximum time interval of 42 months or until recurrence was occurred. Recurrence-free
survival was defined as the time interval between the date of diagnosis and the date of
detection of recurrence or the date of last follow-up without recurrence for breast carcinoma.
The patients were followed up every four months by hospital visits and examinations of
the patients.
2.3. Statistical Analysis
Statistical analysis was performed by Student’s t-test and one-way ANOVA for continuous risk factors found to follow the normal distribution by the use of Kolmogorov–Smirnov
test. Chi-square test was used for categorical risk factors. Mann–Whitney non-parametric
test was used for non-normally distributed continuous risk factors between two groups,
while Kruskal–Wallis non-parametric test was applied for non-normally distributed risk factors between three or more groups. The quantitative non-normally distributed continuous
risk factors are presented as median value (interquartile range, IQR), and the qualitative
risk factors as absolute or relative frequencies. Long rank test was used to compare the
differences between the recurrence curves constructed with the Kaplan–Meier method at
univariate level. Cox proportional hazard regression model was developed to evaluate
the association between MD adherence and nutritional status and recurrence-free patients’
survival, at multivariate level. In Cox proportional hazard regression models, multiple risk
factors (patients’ age and BMI as continuous or categorical risk factors, and histopathological grade of tumor differentiation, tumor size, lymph node metastasis, distant organ
metastases, physical activity, and health-related quality of life as categorical risk factors)
which have been shown that they can exert confounding effects in recurrence-free patients’
survival were included as potential confounding factors. Differences were considered
significant at p < 0.05 at a confidence interval (CI) equal to 95%. The statistical analysis
of the survey data was performed by SPSS 21.0 program (Statistical Package for Social
Sciences, Chicago, IL, USA).
3. Results
3.1. Evaluation of the Study Population’s Anthropometry, Disease and Lifestyle Characteristics and
Recurrence-Free Survival
In total, 114 women, aged 35 to 87 years old (median age 65.5 years, lower-upper
quartiles: 57–75 years), took part in the study. The median BMI was 29.7 Kg/m2 (lowerupper quartiles: 24.8–32.5 Kg/m2 ), with 74% of women having a BMI classifying them in
overweight or obesity.
As far as tumor histopathological type, 80% of patients had ductal breast carcinoma
and 20% of women had lobular breast carcinoma. Regarding the grade of tumor differentiation, 28% had high differentiation grade cancer, 65% medium and 7% had low
differentiation grade cancer. According to TNM staging, 41% of women had stage I cancer,
40% of women had stage II cancer, 8% of women had stage 3 and the rest 11% of women
had stage 4 cancer. According to tumor size (T), 54% of patients were classified as T1, 34%
as T2, 5% as T3 and 6% as T4. A total of 50% of women did not have regional lymph node
metastasis (N0), 39% of patients were classified as N1, 9% of women were classified as
N2 and 2% as N3. As far as distant metastasis is concerned, 89% of women did not have
metastatic cancer (M0), while 11% did (M1).
Physical activity levels were directly classified according to IPAQ. In fact, 55.3% had
low physical activity levels, 21.9% had moderate physical activity levels and 22.8% had
high physical activity levels. The health-related quality of life (EORTC QLQ-C30) median
score was 56.2/100 (range 40/100 to 83.0/100). A total of 50.9% of patients had low health-
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related quality of life (HRQOL, score < 56.2/100) after dichotomization according to the
median value.
Regarding MD adherence, according to the MedDietScore, the median score was 26 (Lowerupper quartile: 25–29) and ranged between 17 and 34. The levels of adherence to the MD were
categorized into tertiles to low (MedDietScore < 25), moderate (25 ≤ MedDietScore < 29) and
high (MedDietScore ≥ 29).
Regarding nutritional status (assessed via MNA), the median score was 25 (Lower-upper
quartile: 22.5–26.5) and ranged between 12.5 and 30. Sixty-eight percent (68%) of the patients
had a good nutritional status (score > 23), 28% were at risk of malnutrition (17 ≤ score ≤ 23)
and 4% of the women were malnourished (score < 17).
After a maximum follow-up of 42 months, 22 patients (19.3%) had relapsed. The median
time to recurrence was 38 months (IQR: 33–40 months) and ranged between 23 to 42 months. At
24 months, 5 patients (4.4%) had relapsed and at 36 months, 15 patients (13.2%) had relapsed.
3.2. Associations between Examined Characteristics and Mediterranean Diet (MD) Adherence
Higher levels of MD adherence were significantly more frequently observed in patients
with lower BMI values (Table 1). Patients with earlier disease stage were significantly more
likely to have higher levels of MD adherence (Table 1). Higher MD adherence was significantly more frequently observed in patients with smaller tumor size and absence of lymph
node metastasis (Table 1). Patients with higher MD adherence showed significantly better
physical activity levels and nutritional status scores and longer recurrence-free survival
times (Table 1). MD adherence was not associated with patients’ age, histopathological
type and grade of tumor differentiation, presence of organ metastasis and health-related
quality of life (via EORTC QLQ-C30) (Table 1).
Table 1. Associations between examined characteristics and Mediterranean diet (MD) adherence.
Mediterranean Diet (MD) Adherence

Characteristics, n = 114
Age (years, IQR *)
BMI (Kg/m2 , IQR)
Histopatological type (n, %)
Ductal breast carcinoma
Lobular breast carcinoma
Tumor grade of differentiation (n, %)
High
Medium
Low
Tumor stage (n, %)
Stage I
Stage II
Stage III + IV
Tumor size (n, %)
T1, ≤2 cm
T2, >2 cm and ≤5 cm
T3 + 4, >5 cm
Presence of lymph node metastasis (n, %)
No
Yes
Presence of distant metastasis (n, %)
No
Yes
Physical activity levels (IPAQ, n, %)
Low
Moderate
High
Health-related quality of life (EORTC
QLQ-C30, n, %)
Low
High
Nutritional status score (median, IQR)
Recurrence-free survival (months, IQR)

Low (33.3%)

Medium (33.3%)

High (33.3%)

p-Value

66.7 (53–72)
32.5 (27.2–36.9)

64.4 (55–76)
28.4 (24.3–32.1)

64.2 (57–78)
27.1 (23.5–30.8)

p = 0.119
p < 0.001
p = 0.682

30 (78,9)
8 (21.1)

29 (76.3)
9 (23.7)

32 (84.2)
6 (15.8)

0 (0.0)
25 (65.8)
13 (34.2)

6 (15.8)
25 (65.8)
7 (18.4)

2 (5.3)
24 (63.2)
12 (31.6)

1 (2.6)
21 (55.3)
16 (42.1)

19 (50.0)
14 (36.8)
5 (13.2)

27 (71.0)
11 (29.0)
0 (0.0)

7 (18.4)
21 (55.3)
10 (26.3)

24 (63.2)
12 (31.6)
2 (5.3)

31 (81.6)
6 (15.8)
1 (2.6)

12 (31.2)
26 (68.4)

23 (60.5)
15 (39.5)

25 (65.8)
13 (34.2)

30 (78.9)
8 (21.1)

37 (97.4)
1 (2.6)

35 (92.1)
3 (7.9)

29 (76.3)
6 (15.8)
3 (7.9)

15 (39.5)
9 (23.7)
14 (36.8)

19 (50.0)
10 (26.3)
9 (23.7)

18 (47.4)
20 (52.6)
23.5 (20.0–26.0)
33.0 (30.0–36.5)

25 (65.8)
13 (34.2)
24.0 (20.5–28.0)
35.5 (33.0–38.5)

15 (39.5)
23 (60.5)
25.5 (21.5–28.5)
38.5 (35.0–41.5)

p = 0.062

p = 0.008

p = 0.017

p = 0.026
p = 0.059
p = 0.015

p = 0.084

* Interquartile Range (IQR).

p = 0.036
p = 0.001
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3.3. Associations between Examined Characteristics and Nutritional Status
Better nutritional status was significantly associated with higher BMI values and
greater levels of MD adherence (Table 2). Patients with better nutritional status showed a
significantly higher prevalence of better health-related quality of life and longer recurrencefree survival times (Table 2). Nutritional status was not associated with patients’ age,
histopathological type and grade of tumor differentiation, disease stage, tumor size, lymph
node and distant metastases and physical activity levels (Table 2).
Table 2. Associations between examined characteristics and nutritional status according to MNA *.
Nutritional Status
Characteristics, n = 114

Well-Nourished
Score > 23
(n = 78, 68.4%)

Risk of Malnutrition
17 ≤ Score ≤ 23
(n = 32, 28.1%)

Malnourished
Score < 17
(n = 4, 3.5%)

Age (years, IQR **)
BMI (Kg/m2 , IQR)
Histopatological type (n, %)
Ductal breast carcinoma
Lobular breast carcinoma
Tumor grade of
differentiation (n, %)
High
Medium
Low
Tumor stage (n, %)
Stage I
Stage II
Stage III + IV
Tumor size (n, %)
T1, ≤2 cm
T2, >2 cm and ≤5 cm
T3 + 4, >5 cm
Presence of lymph node
metastasis (n, %)
No
Yes
Presence of distant metastasis
(n, %)
No
Yes
Physical activity levels
(IPAQ, n, %)
Low
Moderate
High
Health-related quality of life
(EORTC QLQ-C30, n, %)
Low
High
Mediterranean diet score
(median, IQR)
Recurrence-free survival
(months, IQR)

63.5 (57.0–71.5)
32.3 (26.3–33.8)

64.5 (58.0–71.0)
31.8 (25.2–33,2)

65.5 (59.5–72.5)
29.7 (24.1–34,4)

65 (83.3)
13 (16.7)

24 (75.0)
8 (25.0)

2 (50.5)
2 (50.5)

p-Value
p = 0.125
p = 0.022
p = 0.195

p = 0.408
4 (5.1)
52 (66.7)
22 (28.2)

3 (9.4)
19 (59.4)
10 (31.2)

1 (25.0)
3 (75.0)
0 (0.0)

35 (44.9)
28 (35.9)
15 (19.2)

11 (34.4)
16 (50.0)
5 (15.6)

1 (25.0)
2 (50.0)
1 (25.0)

46 (59.0)
23 (29.5)
9 (11.5)

15 (46.9)
14 (43.7)
3 (9.4)

1 (25.0)
2 (50.0)
1 (25.0)

p = 0.672

p = 0.450

p = 0.888
40 (51.3)
38 (48.7)

18 (56.2)
14 (43.8)

2 (50.0)
2 (50.0)
p = 0.737

70 (89.7)
8 (10.3)

28 (87.5)
4 (12.5)

4 (100.0)
0 (0.0)
p = 0.570

41 (52,6)
16 (20.5)
21 (26.9)

19 (59.4)
8 (25.0)
5 (15.6)

3 (75.0)
1 (25.0)
0 (0.0)
p = 0.050

44 (56.4)
34 (43.6)

13 (40.6)
19 (59.4)

1 (25.0)
3 (75.0)

27.0 (23.0–31.0)

26.0 (22.0–30.0)

26.0 (21.0–29.0)

p = 0.046

36.5 (31.5–42.0)

36.0 (31.0–41.0)

34.5 (29.0–39.5)

p = 0.022

* Mini nutritional assessment (MNA). ** Interquartile range (IQR).

3.4. Kaplan–Meier Analysis for the Time to Recurrence after Diagnosis
Kaplan–Meier survival curves indicated that patients with higher MD adherence
had a longer recurrence-free survival than those who did not follow this dietary pattern
to the same extent (Figure 1A, log-rank test, p = 0.0121). Additionally, well-nourished

IQR)

36.5 (31.5–42.0)

36.0 (31.0–41.0)

34.5 (29.0–39.5)

p = 0.022

* Mini nutritional assessment (MNA). ** Interquartile range (IQR).
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same extent (Figure 1A, log-rank test, p = 0.0121). Additionally, well-nourished patients
also had a longer recurrence-free survival time than those at risk of malnutrition or malpatients also had a longer recurrence-free survival time than those at risk of malnutrition
nourished ones (Figure 1B, log-rank test, p = 0.0248).
or malnourished ones (Figure 1B, log-rank test, p = 0.0248).
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p = 0.0087).
2A, log-rank test, p = 0.0087).

Figure 2. Kaplan–Meier survival analysis stratified according to (A) disease stage and (B) body mass
index (BMI) in 114 breast carcinoma patients for recurrence-free patients’ survival.

Patients’ age (log-rank test, p = 0.5849), histopathological type (log-rank test, p = 0.7128),
and grade of tumor differentiation (log-rank test, p = 0.1628) were not associated with the
time to recurrence. Patients who were overweight or obese had a shorter time to recurrence
than patients with a normal BMI (Figure 2B, log-rank test, p = 0.0071).
The health-related quality of life was also associated with the time to recurrence. Patients
with higher EORTC-QLQ-C30 scores had a longer recurrence-free survival (Figure 3A, log-

Curr. Oncol. 2022, 29

7489

rank test, p = 0.0327), than those with lower HRQOL. Moreover, higher physical activity levels
were associated with longer recurrence-free survival (Figure 3B, log-rank test, p = 0.0381).

Figure 3. Kaplan–Meier survival analysis stratified according to (A) health-related quality of life
(HRQOL) and (B) international physical activity questionnaire (IPAQ) in 114 breast carcinoma patients
for recurrence-free patients’ survival.

3.5. Multivariate Analysis for the Time to Recurrence after Diagnosis
In multivariate analysis, high MD adherence was independently associated with
longer recurrence-free patients’ survival after adjustment for potential confounding factors
(Table 3). Patients’ BMI, histopathological type and nutritional status were also independently associated with recurrence-free patients’ survival after adjustment for confounding
factors (Table 3). Patients’ age, histopathological grade, TNM stage, physical activity levels and health-related quality of life did not show any significant impact in multivariate
analysis (Table 3).
Table 3. Multivariate analysis assessing the impact of MD adherence and nutritional status to
recurrence-free patients’ survival.
Recurrence-Free Survival
Characteristics
Age (below/over median value)
BMI (normal weight/overweight and obese)
Histological type (ductal/lobular)
Histological grade (high and medium/Low)
Tumor size (≤2 cm/>2 cm)
Presence of lymph node metastases (No/Yes)
Presence of distant metastases (No/Yes)
Physical activity levels (low/moderate and high)
Health-related quality of life (low/high)
MD adherence
Low (reference)
Moderate
High
Nutritional status
Malnutrition (reference)
Risk of malnutrition
Well-nourished
* Hazard ratio: HR. ** CI: Confidence interval.

HR * (95% CI **)

p-Value

1.10 (0.38–3.03)
3.07 (2.12–4.91)
2.98 (1.48–5.23)
1.35 (0.24–2.43)
0.94 (0.13–5.77)
1.06 (0.20–5.89)
0.97 (0.21–5.12)
1.12 (0.32–2.59)
0.66 (0.21–1.54)

p = 0.558
p = 0.002
p = 0.043
p = 0.312
p = 0.748
p = 0.620
p = 0.407
p = 0.573
p = 0.112
p = 0.017

1.00
0.47 (0.18–0.79)
0.39 (0.15–0.72)
p = 0.046
1.00
0.62 (0.21–1.02)
0.57 (0.18–0.97)
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It should be noted that metastatic disease is such a strong prognostic factor that it
may be difficult to completely remove confounding by adjustment, and thus additional
multivariate analysis was performed excluding patients with distant metastases and adjusting for the remaining three TNM stages (I, II and III). In the relative Cox regression
models developed for MD adherence and nutritional status, almost identical statistics were
produced without revealing any difference with the initial models of Table 3 (data not
shown). This fact may be ascribed to the low number of M1 cases of the study sample.
4. Discussion
In the present prospective study, with a maximum follow-up of 42 months, 19.2% of
patients reported recurrence of the disease. In this aspect, 10–41% of breast cancer patients
will relapse with metastasis to a different body part, depending on TNM stage and tumor
differentiation grade, five years after the end of endocrine therapy [57]. In the meantime,
the cumulative risk of recurrence at the 5th and the 20th year after treatment is 6,8% and
21%, respectively [57]. Stage of cancer [58], tumor size and tumor differentiation grade can
impact disease prognosis [59]. Even at the early stage of T1N0, there is a long-term risk of
recurrence [60].
Our analysis showed that patients with high MD adherence, and normal nutritional
status had a longer recurrence-free survival than those who had lower MD adherence and
those at risk of malnutrition or malnourished ones, with the associations between MD
adherence, nutritional status and recurrence being independent of confounding factors.
Patients who were overweight or obese had a shorter time to recurrence than patients with
a normal BMI, according to the Kaplan–Meier analysis.
Shorter recurrence-free survival was also recorded in patients with larger tumor
size, patients with regional lymph node metastasis, metastatic cancer and more advanced
stage of disease. These findings are in accordance with substantial published evidence
supporting the conclusion that an advanced disease stage and its components (higher
tumor size, presence of lymph node metastasis and presence of distant organ metastases)
are strongly associated with shorter recurrence-free survival in breast cancer [57–60]. In
univariate survival analysis, patients with higher EORTC-QLQ-C30 scores and better
physical activity had a longer time to recurrence than those with lower HRQOL and worse
physical activity; however, these associations did not remain significant after adjustment
for several confounding factors. Patients with high MD adherence showed significantly
lower BMI values than those with low MD adherence, as well as better nutritional status.
Higher BMI was also associated with shorter recurrence-free survival, which is in
line with the current literature, which shows that higher BMI is associated with worse
prognosis [61] in both premenopausal and menopausal women. More specifically, obesity
is associated with shorter overall and cancer-specific survival, and being overweight is
associated with higher overall survival [62]. Warren et al. [63] found that regional relapse
was more common in women who were overweight and obese than those with normal
weight. In fact, weight gain after diagnosis is associated with worse prognosis, and patients
with obesity have a shorter time to relapse and higher mortality rates [64,65].
Adherence to the Mediterranean diet in Greece has gradually decreased [66,67]. In our
study, the median score of MD adherence was 26 with lower-upper quartile: 25–29 which
is quite low concerning the international literature, despite the national and international
guidelines [66,67]. Adherence to this dietary pattern was associated not only with a longer
time to recurrence, but also with better nutritional status. Even though most studies focus
on the association between MD and lower risk of cancer, few studies, including the present
one, investigate its impact on survival or recurrence.
A recent meta-analysis, which included studies published between 2011–2021 [68]
showed that a high-quality diet (via the healthy eating index; HEI-2005, HEI-2015, and
the alternative healthy eating Index; AHEI) after diagnosis is associated with 23% lower
all-cause mortality, but not cancer-specific mortality. Additionally, an improvement of
dietary habits by 10 points, can lower all-cause mortality by 9%. It is important to note that
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Vrieling et al. [30] in their prospective study found a higher all-cause mortality risk with
adherence to an unhealthy diet pattern.
However, Kim et al. [27] did not found a significant association between different
questionnaires that assess MD adherence (AHEI, DQIR, RFS, aMED) and breast cancer
survival. In that study, diet before and after treatment was not associated with mortality
and disease progression. In an earlier study, adherence to a healthy dietary pattern that is
similar to the MD, resulted a significantly lower mortality, but no association was found
with disease progression (recurrence or breast cancer associated death) in patients with
early stages of cancer [69].
Other scores that assess diet quality have failed to find significant associations between
diet quality after diagnosis and survival or relapse [29]. However, Weigl et al. [70] note
that a healthy balanced dietary pattern is important, nonetheless, for the optimal function
of the body. Foods that characterize MD are also sources of bioactive substances with
anticancer, anti-inflammatory [71] and antioxidant activity, and their mode of action has
been described in pre-clinical studies [72,73].
Nutritional assessment in cancer patients is of utmost importance for the early recognition and treatment of malnutrition [74] yet it is often overlooked [75]. In our study, 28%
of patients were at risk of malnutrition and 4% were malnourished. Being malnourished or
at risk of malnutrition can shorten recurrence-free survival, according to both our findings,
and the literature. Malnutrition in breast cancer patients is an independent factor for shorter
survival [39], and more and more studies strengthen the importance of nutritional status in
breast cancer prognosis [76–78].
Moreover, malnutrition is associated with higher mortality in elderly women with
advanced cancer [79], while Bering et al. [80] note that undernutrition in younger patients is
rare, but present and can coexist with overweight and obesity, hence nutritional assessment
in all patients is important, regardless of body weight. Furthermore, assessment should be
repeated frequently, as weight loss before chemotherapy is associated with lower quality
of life in breast cancer patients [81]. Personalized nutritional counselling and support is
important in order for patients to improve their nutritional status [82,83] and decrease the
risk of adverse events and improve prognosis and survival [84].
As far as health-related quality of life is concerned, it was associated with recurrencefree survival, in line with other studies in the literature; however, this association did not
remain significant in multivariate analysis. In women over 65 years old with cancer at
stages 1–3, quality of life is a prognostic factor for 10-year survival [85] and is negatively
affected by recurrence [86]. Patients’ QOL has been improved during the last decades [87].
Even though it worsens at diagnosis, it improves after treatment [88]. Younger patients
have lower HRQOL than older women [89] and women at the early stages of cancer have
better HRQOL in comparison with those with metastatic cancer [90].
Regarding physical activity levels, one in two women presented low physical activity
in our study. Although in this patient group, physical activity is associated with lower
mortality [91,92], and better prognosis [93], physical activity levels drop and stay low after
treatment [91,94–98]. A recent meta-analysis showed that women with higher physical
activity levels have 42% lower all-cause mortality [99]. The mechanism behind the effect
of exercise is the improved anticancer activity of the immune system [100]. Exercise
can improve myoskeletal disorders after treatment [101] and reduce fatigue levels [102].
Exercise can also improve quality of life [103], self-efficacy and self-confidence [104]. In
accordance with the above study, we found that better physical activity was associated
with longer recurrence-free patients’ survival; however, this association did not remain
significant after adjustment for multiple confounding factors.
The limitations of the present study are the small number of participants, with great
heterogeneity regarding characteristics and a relatively short time of follow-up, when
taking into account the improved breast cancer survival. In this aspect, future studies
focusing on specific patients’ subgroups, e.g., only patients with lobular or ductal breast
carcinoma or patients with early disease stage, should be performed. Because the answers
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of the MNA, EORTC-QLQ-C30 and Mediterranean diet score questionnaires were selfreported, the answers may also have recall bias [105]. The study is also an observational
study, hence associations, but not causation can be derived from the data.
In breast cancer, there are many well-known prognostic factors, which, however, were
not available in our cohort. Among the most important prognosticators are several tumor
receptors such as the estrogen receptor (ER), progesterone receptor and human epidermal
growth factor receptor 2 (HER2), as well as the presence of the intraductal component
of the tumor, multifocality, and the treatments received by the patients (radiotherapy or
chemotherapy). This is another limitation of our study and, therefore, future studies should
focus on their potential confounding effects that they may exert on multivariate regression
models assessing the impact of MD adherence and nutritional status on recurrence-free
patients’ survival.
Moreover, in our study population, a rather high proportion of metastatic breast cancer
compared to the existing literature was recorded, which may be ascribed by chance to the
small number of patients [57–60]. By increasing the sample of our study, the proportion of
metastatic breast cancer may be reduced, becoming more representative in accordance with
the existing literature [57–60]. Lastly, the short-term recurrence rate of our study population
is quite high compared to the existing studies [57–60]. Accordingly, by increasing the
sample of our study, the short-term recurrence rate may be lowered, also becoming more
representative and in accordance with the existing literature [57–60].
The present study is one of the few prospective studies that explores the role of the
MD diet on breast cancer prognosis, and we also took into account further parameters such
as health-related quality of life and physical activity levels. The role of nutrition, physical
activity and quality of life in breast cancer patients is also important for their prognosis.
Interventions aimed at facilitating patients in planning and preparing meals can also have
a positive effect on nutritional status, through adequate nutrient intake. Breast cancer
patients are not considered at high risk for malnutrition, and yet poor nutritional status is
present in this group of patients. At the same time, interventions aimed at raising awareness
and informing patients about the positive effect of exercise, in an easy-to-understand way,
with practical solutions (e.g., experiential seminars) can be planned. Health-related quality
of life is another important parameter to be considered by the interdisciplinary team that
treats breast cancer patients, and which can be improved with interventions that combine
healthy eating and gentle exercise [106–108].
5. Conclusions
The present study highlights the importance of the nutritional status and the adherence
to the MD in the prognosis of young and older patients with breast cancer in different
stages of the disease. A high Mediterranean diet adherence and a good nutritional status
were significantly associated with a longer recurrence-free survival.
The impact of the MD on disease progression is still under investigation, while future
studies are expected to analyze the effect of nutritional interventions in order to increase
MD adherence, improving breast cancer survival and prognosis. Our findings regarding
the nutritional status in breast cancer progress strengthen the findings of previous studies
and highlight the importance and need of nutritional assessment, patient education and
intervention for all breast cancer patients.
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